Progesterone Resistance, Aromatase, and Inflammation: The Important Relationships Between Hormones and Inflammation
Tóm tắt
Endometriosis is a complex gynecologic disorder in which alterations of specific biological processes involving both the endocrine and the immune systems have been identified. Recently, a reduced endometrial responsiveness to progesterone has been suggested as a crucial element in the pathophysiology of the disease but it is unclear whether this reduced sensitivity to the steroid is involved in the disease induction or is simply a consequence of the disease condition. Indeed, endometriosis is associated with a local and systemic inflammatory process that is strongly inter-related to the steroid activity, and both the systems mutually interact in a complex loop that strongly influences the disease development and maintenance. The link between prostaglandin E2 (PGE2), aromatase activity, and local estrogen synthesis represents a paradigm of this loop. A better understanding of the pathophysiology of this interaction should enable researchers to develop targeted therapeutics that may limit this self-supporting pathologic loop.
Tài liệu tham khảo
•• Vercellini P, Crosignani P, Somigliana E, et al. ‘Waiting for Godot’: a commonsense approach to the medical treatment of endometriosis. Hum Reprod. 2011;26:3–13. This is an up-to-date critical overview on the current treatments for endometriosis.
Knapp VJ. How old is endometriosis? Late 17th- and 18th-century European descriptions of the disease. Fertil Steril. 1999;72:10–4.
Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20:2698–704.
Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009;15:441–61.
Crosignani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update. 2006;12:179–89.
Barrier BF. Immunology of endometriosis. Clin Obstet Gynecol. 2010;53:397–402.
Bacci M, Capobianco A, Monno A, et al. Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. Am J Pathol. 2009;175:547–56.
• Capobianco A, Monno A, Cottone L, et al. Proangiogenic Tie(2) macrophages infiltrate human and murine endometriotic lesions and dictate their growth in a mouse model of the disease. Am J Pathol. 2011;179:2651–9. This article is a characterization of macrophages infiltrating endometriotic lesions in terms of angiogenic potential.
Nothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril. 2001;76:223–31.
Sinaii N, Cleary SD, Ballweg ML, et al. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod. 2002;17:2715–24.
Matarese G, De Placido G, Nikas Y, Alviggi C. Pathogenesis of endometriosis: natural immunity dysfunction or autoimmune disease? Trends Mol Med. 2003;9:223–8.
Hever A, Roth RB, Hevezi P, et al. Human endometriosis is associated with plasma cells and overexpression of B lymphocyte stimulator. Proc Natl Acad Sci U S A. 2007;104:12451–6.
Flores I, Rivera E, Mousses S, et al. Identification of molecular markers for endometriosis in blood lymphocytes by using deoxyribonucleic acid microarrays. Fertil Steril. 2006;85:1676–83.
Somigliana E, Vigano P, Parazzini F, et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol. 2006;101:331–41.
Vigano P, Somigliana E, Parazzini F, Vercellini P. Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer. Fertil Steril. 2007;88:588–93.
Gentilini D, Perino A, Vigano P, et al. Gene expression profiling of peripheral blood mononuclear cells in endometriosis identifies genes altered in non-gynaecologic chronic inflammatory diseases. Hum Reprod. 2011;26:3109–17.
Koczan D, Guthke R, Thiesen HJ, et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol. 2005;15:251–7.
Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol. 2008;83:804–16.
Voisine P, Ruel M, Khan TA, et al. Differences in gene expression profiles of diabetic and nondiabetic patients undergoing cardiopulmonary bypass and cardioplegic arrest. Circulation. 2004;110:II280–286.
Mote PA, Bartow S, Tran N, Clarke CL. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat. 2002;72:163–72.
Ito K, Utsunomiya H, Yaegashi N, Sasano H. Biological roles of estrogen and progesterone in human endometrial carcinoma–new developments in potential endocrine therapy for endometrial cancer. Endocr J. 2007;54:667–79.
De Vivo I, Huggins GS, Hankinson SE, et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci U S A. 2002;99:12263–8.
Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB. Expression profiling of human breast cancers and gene regulation by progesterone receptors. J Mammary Gland Biol Neoplasia. 2003;8:257–68.
Attia GR, Zeitoun K, Edwards D, et al. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab. 2000;85:2897–902.
Igarashi TM, Bruner-Tran KL, Yeaman GR, et al. Reduced expression of progesterone receptor-B in the endometrium of women with endometriosis and in cocultures of endometrial cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Fertil Steril. 2005;84:67–74.
Wu Y, Strawn E, Basir Z, et al. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis. Epigenetics. 2006;1:106–11.
Bukulmez O, Hardy DB, Carr BR, et al. Inflammatory status influences aromatase and steroid receptor expression in endometriosis. Endocrinology. 2008;149:1190–204.
Burney RO, Talbi S, Hamilton AE, et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology. 2007;148:3814–26.
Gentilini D, Vigano P, Vignali M, et al. Endometrial stromal progesterone receptor-A/progesterone receptor-B ratio: no difference between women with and without endometriosis. Fertil Steril. 2010;94:1538–40.
Gentilini D, Vigano P, Somigliana E, et al. Endometrial stromal cells from women with endometriosis reveal peculiar migratory behavior in response to ovarian steroids. Fertil Steril. 2010;93:706–15.
Backdahl L, Bushell A, Beck S. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Int J Biochem Cell Biol. 2009;41:176–84.
Bromer JG, Zhou Y, Taylor MB, et al. Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response. FASEB J. 2010;24:2273–80.
Heindel JJ, McAllister KA, Worth Jr L, Tyson FL. Environmental epigenomics, imprinting and disease susceptibility. Epigenetics. 2006;1:1–6.
Bruner-Tran KL, Osteen KG. Developmental exposure to TCDD reduces fertility and negatively affects pregnancy outcomes across multiple generations. Reprod Toxicol. 2011;31:344–50.
Bruner-Tran KL, Ding T, Osteen KG. Dioxin and endometrial progesterone resistance. Semin Reprod Med. 2010;28:59–68.
Nayyar T, Bruner-Tran KL, Piestrzeniewicz-Ulanska D, Osteen KG. Developmental exposure of mice to TCDD elicits a similar uterine phenotype in adult animals as observed in women with endometriosis. Reprod Toxicol. 2007;23:326–36.
Stilley JA, Woods-Marshall R, Sutovsky M, et al. Reduced fecundity in female rats with surgically induced endometriosis and in their daughters: a potential role for tissue inhibitors of metalloproteinase 1. Biol Reprod. 2009;80:649–56.
Signorile PG, Spugnini EP, Mita L, et al. Pre-natal exposure of mice to bisphenol A elicits an endometriosis-like phenotype in female offspring. Gen Comp Endocrinol. 2010;168:318–25.
Seli E, Berkkanoglu M, Arici A. Pathogenesis of endometriosis. Obstet Gynecol Clin North Am. 2003;30:41–61.
Colette S, Lousse JC, Defrere S, et al. Absence of aromatase protein and mRNA expression in endometriosis. Hum Reprod. 2009;24:2133–41.
Colette S, Donnez J. Endometriosis. N Engl J Med. 2009;360:1911–2. author reply 1912.
Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril. 2006;85:1307–18.
Bulun SE. Endometriosis. N Engl J Med. 2009;360:268–79.
Bulun SE ZK, Takayama K, Noble L, Michael D, Simpson E, Johns A, Putman M, Sasano H, Carr B. Aromatase expression in endometriosis: biology and clinical perspectives. Understanding and managing endometriosis: advances in research and practice. Quebec City: Parthenon Publishing; 1998.
Bulun SE, Zeitoun KM, Takayama K, Sasano H. Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update. 2000;6:413–8.
Nawathe A, Patwardhan S, Yates D, et al. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG. 2008;115:818–22.
Ferrero S, Venturini PL, Ragni N, et al. Pharmacological treatment of endometriosis: experience with aromatase inhibitors. Drugs. 2009;69:943–52.
Fang Z, Yang S, Gurates B, et al. Genetic or enzymatic disruption of aromatase inhibits the growth of ectopic uterine tissue. J Clin Endocrinol Metab. 2002;87:3460–6.
Noble LS, Takayama K, Zeitoun KM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab. 1997;82:600–6.
Vigano P, Mangioni S, Odorizzi MP, et al. Use of estrogen antagonists and aromatase inhibitors in endometriosis. Curr Opin Investig Drugs. 2003;4:1209–12.
Casper RF. Letrozole versus clomiphene citrate: which is better for ovulation induction? Fertil Steril. 2009;92:858–9.
Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004;19:160–7.
Ailawadi RK, Jobanputra S, Kataria M, et al. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril. 2004;81:290–6.
Amsterdam LL, Gentry W, Jobanputra S, et al. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril. 2005;84:300–4.
Remorgida V, Abbamonte HL, Ragni N, et al. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil Steril. 2007;88:724–6.
Ferrero S, Camerini G, Seracchioli R, et al. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod. 2009;24:3033–41.
American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Aromatase inhibitors in gynecologic practice. Obstet Gynecol. 2008;112:405–7.
Near AM, Wu AH, Templeman C, et al. Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. Fertil Steril. 2011;95:40–5.
Aghajanova L, Velarde MC, Giudice LC. The progesterone receptor coactivator Hic-5 is involved in the pathophysiology of endometriosis. Endocrinology. 2009;150:3863–70.
Kao LC, Germeyer A, Tulac S, et al. Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology. 2003;144:2870–81.
Bulun SE, Cheng YH, Yin P, et al. progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol. 2006;248:94–103.
Aghajanova L, Tatsumi K, Horcajadas JA, et al. Unique transcriptome, pathways and networks in the human endometrial fibroblast response to progesterone in endometriosis. Biol Reprod. 2011;84:801–15.
Bruner-Tran KL, Zhang Z, Eisenberg E, et al. Down-regulation of endometrial matrix metalloproteinase-3 and −7 expression in vitro and therapeutic regression of experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist, tanaproget. J Clin Endocrinol Metab. 2006;91:1554–60.
Nayyar T, Bruner-Tran KL, Piestrzeniewicz-Ulanska D, et al. Developmental exposure of mice to TCDD elicits a similar uterine phenotype in adult animals as observed in women with endometriosis. Reprod Toxicol. 2007;23:326–36.
Vercellini P, Fedele L, Pietropaolo G, et al. Progestogens for endometriosis: forward to the past. Hum Reprod Update. 2003;9:387–96.